Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $35

Craig-Hallum analyst Chase Knickerbocker has maintained a Buy rating on Eton Pharmaceuticals (NASDAQ: ETON) and raised the price target from $30 to $35.